Changes in Hong Kong stocks | Yiming Onko-B (01541) rose nearly 10% in the afternoon, the subsidiary Yiming Kell increased its strategic capital by 50 million to accelerate the layout of non-tumor pipelines

The Zhitong Finance App learned that Yiming Onko-B (01541) rose nearly 10% in the afternoon. As of press release, it had risen 8.42% to HK$3.155, with a turnover of HK$1,5661 million.

According to the news, Yiming Angke issued an announcement stating that the subsidiary Yiminkell signed a capital increase agreement with Biotech Sailing, New Territories Chuangyuan and Wang Xueyan. The three investors pledged 465,000 yuan of expanded registered capital of Yiminkel at a total cost of 50 million yuan, accounting for about 15.83% of its expanded shares.

According to public information, Yiming Kyle focuses on research and development of macromolecular drugs in the fields of cardiovascular diseases and metabolic diseases such as pulmonary hypertension. The purpose of this capital increase is to further enrich Yiminkel's financial resources and accelerate the development process of innovative drugs in the field of cardiovascular diseases and metabolic diseases such as pulmonary hypertension, and marks the steady implementation of Yiming Angke's “tumor+non-tumor” two-wheel drive strategy.